Recombinant Human MAPK3 293 Cell Lysate
- Gene Information
- Related Products
|Description :||Antigen standard for mitogen-activated protein kinase 3 (MAPK3), transcript variant 1 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.|
|Source :||HEK 293 cells|
|Components :||This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).|
|Size :||0.1 mg|
|Storage Instruction :||Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.|
|Applications :||ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.|
|Gene Name :||MAPK3 mitogen-activated protein kinase 3 [ Homo sapiens ]|
|Official Symbol :||MAPK3|
|Synonyms :||MAPK3; mitogen-activated protein kinase 3; PRKM3; ERK1; p44erk1; p44mapk; MAPK 1; MAP kinase 1; MAP kinase 3; MAP kinase isoform p44; insulin-stimulated MAP2 kinase; mitogen-activated protein kinase 1; extracellular signal-related kinase 1; extracellular signal-regulated kinase 1; microtubule-associated protein 2 kinase; ERT2; ERK-1; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; p44-ERK1; p44-MAPK; MGC20180;|
|Gene ID :||5595|
|mRNA Refseq :||NM_001040056|
|Protein Refseq :||NP_001035145|
|UniProt ID :||P27361|
|Chromosome Location :||16p11.2|
|Pathway :||ALK1 signaling events, organism-specific biosystem; ARMS-mediated activation, organism-specific biosystem; ATF-2 transcription factor network, organism-specific biosystem; Activated TLR4 signalling, organism-specific biosystem; Activation of the AP-1 family of transcription factors, organism-specific biosystem; Acute myeloid leukemia, organism-specific biosystem; Acute myeloid leukemia, conserved biosystem;|
|Function :||ATP binding; MAP kinase activity; MAP kinase activity; nucleotide binding; phosphatase binding; phosphotyrosine binding; protein binding; protein serine/threonine kinase activity;|
|◆ Recombinant Protein|
|MAPK3-061H||Recombinant Human MAPK3 Protein, MYC/DDK-tagged, C13 and N15-labeled||+Inquiry|
|MAPK3-5350M||Recombinant Mouse MAPK3 Protein, His (Fc)-Avi-tagged||+Inquiry|
|MAPK3-1083H||Recombinant Human MAPK3 Protein (A2-P379), GST tagged||+Inquiry|
|MAPK3-1050H||Active Recombinant Human MAPK3 Protein, His/GST-Tagged||+Inquiry|
|MAPK3-1363H||Recombinant Human MAPK3 Protein, His (Fc)-Avi-tagged||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (7)Ask a question
Dysregulation of MAPK3 signaling has been implicated in the pathogenesis of several diseases. Aberrant activation of MAPK3 is associated with cancer development and progression, as it promotes cell proliferation and survival. MAPK3 signaling is also involved in cardiovascular diseases, contributing to vascular remodeling and hypertrophy. In neurodegenerative diseases, dysregulated MAPK3 activity contributes to neuronal dysfunction and apoptosis.
Future research in MAPK3 aims to elucidate the intricate signaling network and identify novel regulatory mechanisms. Understanding the crosstalk between MAPK3 and other signaling pathways will be crucial for developing targeted therapies. Additionally, exploring the role of MAPK3 isoforms in different cellular contexts and disease states will provide valuable insights. Furthermore, the development of more specific and potent inhibitors with reduced toxicity profiles is a focus for future therapeutic interventions.
MAPK3, also known as ERK1 (Extracellular Signal-Regulated Kinase 1), is a serine/threonine kinase involved in cell signaling pathways. It consists of 379 amino acids and exhibits a conserved catalytic domain. MAPK3 plays a crucial role in regulating cell proliferation, differentiation, and survival by phosphorylating downstream targets such as transcription factors and other kinases.
MAPK3 signaling exerts its effects through phosphorylation of downstream targets. It phosphorylates various transcription factors, including ELK1 and c-Fos, leading to changes in gene expression. MAPK3 also phosphorylates other kinases, such as p90RSK, which further propagate the signal to regulate cellular processes like cell cycle progression, apoptosis, and differentiation.
One challenge is the potential for off-target effects when targeting MAPK3, as it is involved in multiple signaling pathways. Additionally, resistance to MAPK3 inhibitors can emerge due to compensatory signaling mechanisms and genetic alterations. Another challenge lies in achieving selective inhibition of specific MAPK3 isoforms without affecting other closely related kinases.
The activity of MAPK3 is tightly regulated by various mechanisms. Activation of MAPK3 involves dual phosphorylation of threonine and tyrosine residues by upstream kinases. Conversely, dephosphorylation by phosphatases can inactivate MAPK3. Additionally, scaffolding proteins and interacting partners can modulate its activity by facilitating or inhibiting its phosphorylation or by regulating its subcellular localization.
Inhibition of MAPK3 activity or downstream effectors represents a potential therapeutic approach. Small molecule inhibitors targeting MAPK3 kinase activity, such as U0126 and PD98059, have been developed. Monoclonal antibodies against MAPK3 or its downstream effectors are also being investigated. Combination therapies targeting multiple components of the MAPK3 signaling pathway are being explored to enhance efficacy and overcome resistance.
Customer Reviews (3)Write a review
Exemplary precision and unblemished dependability render it my most cherished research ally. -
Presenting exceptional reliability and stability, the experimental reagent establishes a robust foundation for my experiments. -
Exquisitely crafted packaging design adds convenience to the usage of this protein reagent and exudes a sense of sophistication. -
Ask a Question for All MAPK3 Products
Required fields are marked with *
My Review for All MAPK3 Products
Required fields are marked with *